treatment
Salmeterol treatment       resulted in significantly greater improvements from baseline compared with       zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0       L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001),        and percentage of days and nights with no supplemental albuterol use (30.5% vs       11.3%; P </= .001).
 @OBJECT$  @PREDICAT$  @SUBJECT$        resulted in significantly greater improvements from baseline compared with       zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0       L/min; P </= .001), percentage of symptom-free days (22.4% vs 8.8%; P </= .001),        and percentage of days and nights with no supplemental albuterol use (30.5% vs       11.3%; P </= .001).